Lenalidomide with rituximab for previously treated follicular lymphoma - technology appraisal guidance [TA627]

NICE has recommended lenalidomide with rituximab, within its marketing authorisation, as an option for previously treated follicular lymphoma (grade 1 to 3A) in adults. It is only recommended if the company provides lenalidomide according to the commercial arrangement.

National Institute for Health and Care Excellence